Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A compound of the Formula I:



Formula I

wherein:

R^1 and R^2 are independently selected from hydrogen, (1-6C)alkylsulfonyl, phenyl$(CH_2)_u$- wherein u is 0, 1, 2, 3, 4, 5 or 6, (1-6C)alkanoyl, (1-6C)alkyl, (1-6C)alkoxycarbonyl, (3-6C)cycloalkyl$(CH_2)_x$- in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring, or **R^1 and R^2** together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another hetero atom selected from N or O;

wherein the (1-6C)alkyl, the (1-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy(1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, mono(1-6C)alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl, –N(R^d)C(O)(1-6C)alkyl in which R^d is hydrogen or (1-6C)alkyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring, or a 5 or 6 membered heteroaryl ring,

wherein the (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy and (1-6C)alkoxy(1-6C)alkoxy(1-6C)alkoxy groups and the (1-6C)alkyl groups of the mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, mono(1-6C)alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl and/or -N(R^d)C(O)(1-6C)alkyl groups are optionally substituted by one or more hydroxy groups;

wherein the phenyl is optionally substituted by one or more groups independently selected from halo, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups

are optionally substituted by one or more groups independently selected from hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino;

and wherein any heterocyclic and heteroaryl rings within R^1 and/or R^2 are optionally independently substituted by one or more of the following: (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl, hydroxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, a saturated or partially saturated 3 to 7 membered heterocyclic ring or $-C(O)(CH_2)_zY$ wherein z is 0, 1, 2 or 3 and Y is selected from hydrogen, hydroxy, (1-4C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

and provided that when R^1 and/or R^2 is a (1C)alkanoyl group, then the (1C)alkanoyl is not substituted by fluoro or hydroxy;

R^3 and R^4 are independently selected from hydrogen, (1-6C)alkyl or (1-6C)alkoxy, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, mono(1-6C)alkylcarbamoyl or di-[(1-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (1-4C)alkyl, (1-4C)alkoxy, hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

or one of **R^3** and **R^4** is as defined above and the other represents a group **$-NR^1R^2$** as defined above;

A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;

R^5 is selected from cyclopropyl, cyano, halo, (1-6C)alkoxy or (1-6C)alkyl, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;

n is 0, 1, 2 or 3;

L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents $-C(R^aR^b)C(O)N(R^9)-$, $-N(R^8)C(O)C(R^aR^b)-$, $-N(R^8)C(O)N(R^9)-$, $-N(R^8)C(O)O-$, or $-OC(O)-N(R^9)-$, wherein R^8 and R^9 independently represent hydrogen or (1-6C)alkyl and wherein R^a and R^b independently represent hydrogen or (1-6C)alkyl or R^a and R^b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl;

B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;

$\mathbf{R^6}$ is selected from halo, cyano, oxo, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, and $-N(R^c)C(O)$(1-6C)alkyl in which R^c is hydrogen or (1-6C)alkyl; or

$\mathbf{R^6}$ is selected from (1-6C)alkyl, $-S(O)_p-$(1-6C)alkyl wherein p is 0, 1 or 2, or (1-6C)alkoxy, wherein the (1-6C)alkyl, $-S(O)_p-$(1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring; and

wherein the (3-7C)cycloalkyl ring and saturated or partially saturated 3 to 7 membered heterocyclic ring are optionally independently substituted by one or more groups selected from (1-6C)alkyl; and

m is 0, 1, 2 or 3;

and when B is a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group, the rings and the bicyclic group optionally bear 1 or 2 oxo or thioxo substituents;

and salts thereof.

2. (Original): A compound of Formula I according to Claim 1, wherein:

R^6 is selected from halo, cyano, a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group $-N(R^c)C(O)$(1-6C)alkyl in which R^c is hydrogen or (1-6C)alkyl; or

R^6 is selected from (1-6C)alkyl or (1-6C)alkoxy, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by one or more groups independently selected from cyano, fluoro, hydroxy, (1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, a (3-7C)cycloalkyl ring or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

and salts thereof.

3. (Original): A compound of the Formula I according to claim 1, wherein:

R^1 and R^2 are independently selected from hydrogen, (1-6C)alkylsulfonyl, phenyl$(CH_2)_u$- wherein u is 0, 1, 2, 3, 4, 5 or 6, (1-6C)alkanoyl, (1-6C)alkyl, (1-6C)alkoxycarbonyl, or (3-6C)cycloalkyl$(CH_2)_x$- in which x is 0, 1, 2, 3, 4, 5 or 6 or **R^1 and R^2** together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another hetero atom selected from N or O;

wherein the alkyl and the cycloalkyl groups are optionally substituted by one or more groups selected from fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (1-4C)alkyl, hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

and wherein the phenyl is optionally substituted by one or more groups selected from halo, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino, wherein the (1-6C)alkyl or (1-6C)alkoxy are optionally substituted by hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino;

R^3 and R^4 are independently selected from hydrogen, (1-6C)alkyl or (1-6C)alkoxy wherein the alkyl and the alkoxy groups are optionally substituted by one or more

groups selected from fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (1-4C)alkyl, hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

or one of **R^3** and **R^4** is as defined above and the other represents a group **$-NR^1R^2$** as defined above;

R^5 is selected from cyano, halo, (1-6C)alkoxy or (1-6C)alkyl optionally substituted by cyano or by one or more fluoro;

B represents a (3-7C)cycloalkyl ring, an aryl or a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;

R^6 is selected from halo, cyano, a saturated or partially saturated 3 to 7 membered heterocyclic ring or an alkanoylamino group $-N(R^c)C(O)$(1-6C)alkyl in which R^c is hydrogen or (1-6C)alkyl; or **R^6** is selected from (1-6C)alkyl or (1-6C)alkoxy, wherein the alkyl and the alkoxy groups are optionally substituted by one or more groups selected from cyano, fluoro, hydroxy, (1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, or a saturated or partially saturated 3 to 7 membered heterocyclic ring; and

m **is 0, 1, 2 or 3;** and when m is at least 2 then two substituents on adjacent carbon atoms in ring B may together represent a methylenedioxy group;

and wherein A, L and n are as defined in Claim 1.
and salts thereof.

4. (Previously amended): A compound according to Claim 1 wherein A is selected from phenyl, pyridyl, thiazolyl, thiadiazolyl or pyrimidinyl.

5. (Prevously amended): A compound according to claim 1 wherein B is selected from phenyl, 2,3-di-hydro-indenyl, piperidinyl, pyridyl, pyrazolyl, isothiazolyl, thiadiazolyl, isoxazolyl, benzodioxinyl, benzodioxolyl or tetrahydropyranyl

6. (Previously amended): A compound according to claim 1 wherein L is selected from $-N(R^8)C(O)N(R^9)-$, $-N(R^8)C(O)O-$ or $-N(R^8)C(O)CH_2-$ wherein R^8 and R^9 independently represent hydrogen or (1-6C)alkyl.

7. (Previously amended): A compound according to claim 1 wherein R^1 and R^2 are both hydrogen or R^1 is hydrogen or (1-6C)alkyl and R^2 is (1-6C)alkyl
wherein (1-6Calkyl) is optionally substituted by hydroxy, amino, mono(1-6C)alkylamino or di(1-6C)alkylamino, carbamoyl, (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, $-N(R^d)C(O)$(1-6C)alkyl in which R^d is hydrogen or (1-6C)alkyl, aryl (particularily phenyl), a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring;
wherein the (1-6C)alkoxy, mono(1-6C)alkylamino and $-N(R^d)C(O)$(1-6C)alkyl groups are optionally substituted by hydroxy;
wherein an aryl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring is optionally substituted by (1-4C)alkyl, (1-4C)alkoxy or $-C(O)CH_2Y$ wherein Y is selected from hydroxy or di(1-6C)alkylamino.

8. (Previously amended): A compound according to claim 1 wherein R^3 and R^4 are both hydrogen.

9. (Canceled)

10. (Original): A compound according to Claim 1 which is any one or more of examples 1 to 152 or a salt thereof.

11. (Previously amended): A pharmaceutical composition which comprises a compound of the Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically acceptable diluent or carrier.

12. (Previously canceled)

13. (Previously canceled)

14. (Previously canceled)

15. (Currently amended): A process for preparing a compound of formula I, or salt thereof, as defined in Claim 1, or a pharmaceutically acceptable salt thereof (wherein R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11} L , ring A and ring B, n and m are, unless otherwise specified, as defined in Claim 1) comprising:

(a) For compounds of the formula I wherein L is -N(R^8)C(O)N(H)-, the reaction of a compound of the formula II:



II

wherein R^1, R^2, R^3, R^4, R^5, R^8, n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the formula IV:



IV

wherein R^6, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(b) For compounds of the formula I wherein L is -N(R^8)C(O)N(H)-, the reaction of a compound of the formula II as defined above with an aryl carbamate of the formula III:



III

wherein Ar is a suitable aryl group and R^6, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(c) For compounds of the formula I wherein L is $N(R^8)C(O)$-O-, the reaction of a compound of the formula II as defined above with a compound of the formula XI:



XI

wherein Lg^1 is a suitable displaceable group and R^6, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(d) For compounds of the formula I wherein L is $N(R^8)C(O)C(R^aR^b)$, the reaction of a compound of the formula II as defined above with a compound of the formula IX:



IX

wherein Lg^2 is a suitable displaceable group, R^x-C(O)-O- or R^x-O- (wherein R^x is a suitable alkyl or aryl group) and R^6, R^a, R^b, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(e) For compounds of the formula I wherein L is $-N(R^8)C(O)N(H)$-, the reaction of a compound of the formula II as defined above with a trichloroacetylamine of the formula XIII:



XIII

wherein R^6, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(f) For compounds of the formula I wherein L is $-C(R^aR^b)C(O)N(R^9)$-, the reaction of a compound of the formula XIV:



XIV

wherein Lg^2 is a suitable displaceable group as described above and R^1, R^2, R^3, R^4, R^5, R^a, R^b, n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula XV:



XV

wherein R^6, R^9, m and B have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(g) The reaction of a compound of the formula XVI:



XVI

wherein Lg^3 is a suitable displaceable group ~~for example halogeno methyl sulfonyl, methylthio or aryloxy~~ and R^3, R^4, R^5, R^6, n, m, A, B and L have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula HNR^1R^2, wherein R^1 and R^2 have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(h) The reaction of a compound of the formula XVII:



XVII

wherein Lg^4 is a suitable displaceable group or a sulfonyloxy group and R^5, R^6, n, m, A, B and L have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an alkyne of the formula XVIII:



XVIII

wherein R^1, R^2, R^3 and R^4 have any of the meanings defined hereinbefore except that any functional group is protected if necessary; or

(i) For compounds of the formula I wherein L is -N(H)C(O)N(R^9)-, the reaction of an isocyanate of the formula XIX:



XIX

wherein R^1, R^2, R^3, R^4, R^5, n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula XV as defined above; or

(j) For compounds of the formula I wherein L is -N(H)C(O)N(R^9)-, the reaction of a compound of the formula XX:



XX

wherein Ar is a suitable aryl group and R^1, R^2, R^3, R^4, R^5, n and A have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula XV as defined above.

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt.

16. (Previously amended): A compound selected from Formulae II, XIV, XVI, XIX and XX as defined in Claim 15, wherein A is a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl

or a compound of Formula VIc:



VIc

or salt thereof, wherein A is a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl and Lg^3, R^3, R^4, R^5 and n are as defined in Claim 15.

17. (Previously presented): A method of inhibiting Tie2 receptor tyrosine kinase in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

18. (Previously Presented): A method for producing an anti-angiogenic effect in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

19. (New): A compound of the Formula I:



Formula I

wherein:

R^1 and R^2 are independently selected from hydrogen, (1-6C)alkylsulfonyl, phenyl$(CH_2)_u$- wherein u is 0, 1, 2, 3, 4, 5 or 6, (1-6C)alkanoyl, (1-6C)alkyl, (1-6C)alkoxycarbonyl, (3-6C)cycloalkyl$(CH_2)_x$- in which x is 0, 1, 2, 3, 4, 5 or 6, or a 5 or 6 membered heteroaryl ring, or **R^1 and R^2** together with the nitrogen atom to which they are attached represent a saturated or partially saturated 3 to 7 membered heterocyclic ring optionally containing another hetero atom selected from N or O;

wherein the (1-6C)alkyl, the (1-6C)alkanoyl and the (3-6C)cycloalkyl groups are optionally substituted by one or more groups independently selected from fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy(1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, mono(1-6C)alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl, –N(R^d)C(O)(1-6C)alkyl in which R^d is hydrogen or (1-6C)alkyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring, or a 5 or 6 membered heteroaryl ring,

wherein the (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy and (1-6C)alkoxy(1-6C)alkoxy(1-6C)alkoxy groups and the (1-6C)alkyl groups of the mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, mono(1-6C)alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl and/or -N(R^d)C(O)(1-6C)alkyl groups are optionally substituted by one or more hydroxy groups;

wherein the phenyl is optionally substituted by one or more groups independently selected from halo, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by one or more groups independently selected from hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino;

and wherein any heterocyclic and heteroaryl rings within R^1 and/or R^2 are optionally independently substituted by one or more of the following: (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkoxy(1-4C)alkyl, hydroxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, a saturated or partially saturated 3 to 7 membered heterocyclic ring or -C(O)$(CH_2)_z$Y wherein z is 0, 1, 2 or 3 and Y is selected from hydrogen, hydroxy, (1-4C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;

and provided that when R^1 and/or R^2 is a (1C)alkanoyl group, then the (1C)alkanoyl is not substituted by fluoro or hydroxy;

R^3 and R^4 are independently selected from hydrogen, (1-6C)alkyl or (1-6C)alkoxy, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by one or more groups independently selected from: fluoro, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, amino, mono(1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, mono(1-6C)alkylcarbamoyl or di-[(1-6C)alkyl]carbamoyl, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a 5 or 6 membered heteroaryl ring, wherein said heterocyclic and heteroaryl rings are optionally independently substituted by one or more of the following: (1-4C)alkyl, (1-4C)alkoxy, hydroxy, amino, mono(1-6C)alkylamino or di-[(1-6C)alkyl]amino or a saturated or partially saturated 3 to 7 membered heterocyclic ring;
or one of R^3 and R^4 is as defined above and the other represents a group $-NR^1R^2$ as defined above;

A represents an aryl group or a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl;

R^5 is selected from cyclopropyl, cyano, halo, (1-6C)alkoxy or (1-6C)alkyl, wherein the (1-6C)alkyl and the (1-6C)alkoxy groups are optionally substituted by cyano or by one or more fluoro;

n is 0, 1, 2 or 3;

L is attached meta or para on ring A with respect to the point of attachment of the ethynyl group and represents $-C(R^aR^b)C(O)N(R^9)-$, $-N(R^8)C(O)C(R^aR^b)-$, $-N(R^8)C(O)N(R^9)-$, $-N(R^8)C(O)O-$, or $-OC(O)-N(R^9)-$, wherein R^8 and R^9 independently represent hydrogen or (1-6C)alkyl and wherein R^a and R^b independently represent hydrogen or (1-6C)alkyl or R^a and R^b together with the carbon atom to which they are attached represent (3-6C)cycloalkyl;

B represents a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring, an aryl group, a 5 or 6 membered heteroaryl ring selected from furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl,

pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazinyl, or a 8, 9 or 10 membered bicyclic group which optionally contains 1, 2, 3 or 4 heteroatoms independently selected from N, O and S and which is saturated, partially saturated or aromatic;

R^6 is independently selected from halo, cyano, oxo, (3-7C)cycloalkyl, a saturated 3 to 7 membered heterocyclic ring (optionally substituted by (1-4C)alkyl), -N(R^c)C(O)(1-6C)alkyl wherein R^c is hydrogen or (1-6C)alkyl), (1-6C)alkyl (optionally substituted by up to three groups independently selected from halo) or (1-6C)alkoxy; and

m is 1 or 2;

and when B is a (3-7C)cycloalkyl ring, a saturated or partially saturated 3 to 7 membered heterocyclic ring or a saturated or partially saturated 8, 9 or 10 membered bicyclic group, the rings and the bicyclic group optionally bear 1 or 2 oxo or thioxo substituents;

and salts thereof.